详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Prospects of Immunotherapy for Triple-Negative Breast Cancer.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]School of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China. [2]School of Nursing of Jinan University, Jinan University, Guangzhou, China. [3]School Public Health, Southern Medical University (No: 3210090112), Guangzhou, China. [4]School of Medicine, Jinan University, Guangzhou, China. [5]Department of Cellular Biology, Institute of Biomedicine, National Engineering, Research Center of Genetic Medicine, Key Laboratory of Bioengineering Medicine of Guangdong Province, The National Demonstration Center for Experimental Education of Life Science and Technology, Jinan University, Guangzhou, China. [6]The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.

出处：

DOI：

ISSN：

关键词： triple-negative breast cancers immunotherapy immune checkpoint molecules PD1/PD-L1 pathway CTLA-4 combination therapy

摘要：

In the classification and typing of breast cancer, triple-negative breast cancer (TNBC) is one type of refractory breast cancer, while chemotherapy stays in the traditional treatment methods. However, the impact of chemotherapy is short-lived and may lead to recurrence due to incomplete killing of tumor cells. The occurrence, development, and relapse of breast cancer are relevant to T cell dysfunction, multiplied expression of related immune checkpoint molecules (ICIs) such as programmed death receptor 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) produce immunosuppressive effect. Immunotherapy (namely, immune checkpoint inhibitors, adoptive cellular immunotherapy, CAR-T immunotherapy and some potential treatments) provides new hope in TNBC. This review focuses on the new immune strategies of TNBC patients.Copyright © 2022 Qiu, Zhang, Yan, Xiao, Ma, Lin, Wu, Li, Wang, Liu, Ma and Ma.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

第一作者：

第一作者机构： [1]School of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China.

共同第一作者：

通讯作者：

通讯机构： [1]School of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China. [6]The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma. [2]Decreased serum soluble programmed cell death ligand-1 level as a potential biomarker for missed miscarriage [3]Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model. [4]Exosome CTLA-4 Regulates PTEN/CD44 Signal Pathway in Spleen Deficiency Internal Environment to Promote Invasion and Metastasis of Hepatocellular Carcinoma [5]Clinical Evidence for Chinese Medicine Combination Therapy [6]Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer [7]Differential effect on symptoms treated with traditional Chinese medicine and western combination therapy in RA patients [8]Thiophene donor for NIR-II fluorescence imaging-guided photothermal/photodynamic/chemo combination therapy. [9]Combination therapy with artemether and enalapril improves type 1 diabetic nephropathy through enhancing antioxidant defense. [10]Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma (Open Access)